LifeArc Becomes Technology Transfer Partner to London School of Hygiene & Tropical Medicine
News Jul 26, 2017
LifeArc, the medical research charity previously known as MRC Technology, has signed an agreement with the London School of Hygiene & Tropical Medicine to provide a range of technology transfer services.
LifeArc has expertise in protecting and managing intellectual property, evaluating the translational potential of research portfolios and advising on funding and development pathways. The charity has over 25 years’ experience of providing technology transfer support to a range of organisations, including the Medical Research Council and various charities and non-profit organisations. The London School of Hygiene & Tropical Medicine is a world-leading centre for research and postgraduate education in public and global health, with staff working in over 100 countries to improve health worldwide.
“LifeArc exists to make a difference for patients and to achieve this we have to make sure that promising medical research is progressed. The London School of Hygiene & Tropical Medicine shares our aim of addressing major public and global health challenges, and we look forward to providing the expertise to help them maximise their research portfolio,” said Andrew Farquharson, Executive Director, Technology Transfer at LifeArc.
Professor Peter Piot, Director of the London School of Hygiene & Tropical Medicine, said: “The world is facing unprecedented challenges in the form of infectious and chronic conditions, and emerging health threats. We need to innovate to meet these challenges and improve health for all. This exciting partnership with LifeArc will intensify efforts to translate our research in ways that have a tangible impact.”.
Unraveling How Mesenchymal Stem Cells From Gum Tissue Accelerate Wound HealingNews
To assist with wound healing, mesenchymal stem cells from the gum tissue secrete extracellular vesicles that contain the anti-inflammatory signaling molecule IL-1RA.READ MORE
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.